Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGC001 in healthy volunteers
NCT07079618Phase 1Completed
- Sponsor
- Sungen Biomedical
- Start
- Aug 2024
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in myocardial infarction (MI) comparing SGC001 with Placebo (2 arms). Primary endpoints: Adverse Events at 57 days, Serious Adverse Events at 57 days and 2 more. Started Aug 2024; status: completed.
02
Drugs
SGC001
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT07079618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07079618.